FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasnington,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL						
OMB Number: 3235-02						
Estimated average burden						
hours por rosponso:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ORBIMED ADVISORS LLC					2. <u>A</u>	2. Issuer Name and Ticker or Trading Symbol Aerpio Pharmaceuticals, Inc. [ARPO]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Office of the Utility Control of the Control						
	INGTON A	First) AVENUE	(Middle)			Date 2/08/		of Earliest Transaction (Month/Day/Year) 2020							Officer (give title Other (specify below) below)					
54TH FLOOR 4. If Am							f Amendment, Date of Original Filed (Month/Day/Year)							. Individual o	r Joint/G	roup Fili	ng (Chec	k Applica	ble	
(Street) NEW Y	ORK N	ΙΥ	10022-	4629										Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person						
(City)	(5	State)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)		Date		2. Transaction Date Month/Day/Year		Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		(A) or 3, 4 and	Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						\perp			Code	V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)						
Common	Stock			12/08	/2020				Х		21,400	A	\$0.96	21,4	00		I	See Footnotes ⁽¹⁾		
Common	Stock			12/08	/2020				S		21,400	D	\$1.96(3)	0			I	See Footnotes ⁽¹⁾		
Common	Stock													5,193,	,946		I	See Footno	tes ⁽²⁾⁽⁴⁾	
			Table								sposed o									
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed 4. Execution Date, if any			ansaction		5. Number of		Exerction Da /Day/Y		of Securi	ng e Security	Derivative Security (Instr. 5) Benefi Owned Follow Report		rities Form: Cicially Direct or Ind ving (I) (Insected action(s)		nip India Bendon O) Own ct (Inst	eficial ership	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (Right to Buy)	\$0.96	12/08/2020			х			21,400	(5)	١	06/28/2029	Common Stock	21,400	\$0	()	I	See Foot	enotes ⁽²⁾⁽⁵⁾	
		FReporting Person*															,	·		
(Last)	INGTON A	(First)		liddle)																
(Street) NEW Y	ORK	NY	10	0022-462	29	,														
(City)		(State)	(Z	ip)																
		Reporting Person*	•																	
(Last) 601 LEX 54TH FI	INGTON A	(First) AVENUE	(M	iddle)		.,														
(Street)	ORK	NY	10	0022																

Explanation of Responses:

(State)

(City)

member of OrbiMed Capital GP V LLC ("GP V"), which is the general partner of OrbiMed Private Investments V, LP ("OPI V"). Pursuant to an agreement with OrbiMed Advisors and GP V, Khuong is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V.

- 2. Each of the GP V, OrbiMed Advisors, and Khuong disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- 3. The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.94 to \$2.00. The Reporting Persons
- 4. These Shares are held of record by OPI V. By virtue of the relationships described in footnote 1, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI A ranks shaded and related to the control of the Charles and the Cha
- 5. This option was granted to Khuong on June 18, 2019 and vested on the first anniversary of the grant date. Pursuant to an agreement with OrbiMed Advisors and GP V, Khuong is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V.

/s/ Douglas Coon, Chief Compliance Officer, OrbiMed 12/09/2020 **Advisors LLC**

/s/ Douglas Coon, Chief

Compliance Officer, OrbiMed Capital GP V LLC 12/09/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.